Nasdaq Flags Bid Price Deficiency for Silexion; Hearings Panel to Weigh Listing Fate
SLXN is trading near its 52-week low of $0.236 (9.0% above the low) on light trading volume (0.2× avg).
Summary
Silexion received a Nasdaq Staff Determination letter citing a bid price deficiency under Rule 5550(a)(2). The hearings panel will consider the deficiency in deciding continued listing, compounding the same-day shareholder rejection of the reverse split and share authorization increase.
Key Events · Legal and Risk Events · SLXN
-
Nasdaq Bid Price Deficiency Notice
A Nasdaq Staff Determination letter received on September 25, 2026, cites 30 consecutive business days below the $1.00 minimum bid price under Listing Rule 5550(a)(2).
-
Hearings Panel to Decide Listing
The Nasdaq hearings panel will weigh the bid price deficiency in deciding whether Silexion can remain listed on the Nasdaq Capital Market.
-
Shareholder Vote Rejection Compounds Risk
Same-day shareholder rejection of the 175M share authorization increase (24.6% support) and 1-for-15 reverse split (25.9% support) leaves the company without the tools to cure the deficiency.
-
Trading Continues for Now
Ordinary shares (SLXN) and warrants (SLXNW) continue to trade on Nasdaq with no immediate effect from the letter.
Analysis · SLXN · Life Sciences
A formal Nasdaq Staff Determination letter landed on September 25, 2026, confirming that Silexion's ordinary shares had traded below the $1.00 minimum bid price for 30 consecutive business days. The Nasdaq hearings panel will now factor this deficiency into its decision on whether the company can remain listed on the Nasdaq Capital Market. The timing is particularly acute: on the same day, shareholders rejected both the 175M share authorization increase and the 1-for-15 reverse split, stripping the company of the very tools it sought to cure the deficiency. While the shares and warrants continue to trade for now, the delisting risk is now formally before the hearings panel.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $0.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.24 to $42.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.